Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
The EMERALD-3 Phase III trial demonstrated a statistically significant improvement in progression-free survival for Imfinzi plus Imjudo in patients with unresectable liver cancer.
Published: June 2, 2026
Updated: June 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Liver Cancer
Asset: Oncology
Indication: Liver Cancer
Trial SummaryCLN
Phase III
Liver Cancer
Primary Endpoint
PFS
Status
Positive
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
Portfolio teams should consider the implications of this combination therapy for future treatment guidelines and market access strategies.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor regulatory submissions and potential market launch timelines following these trial results.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.